APM
TRVI icon

Avidity Partners Management’s Trevi Therapeutics TRVI Stock Holding History

Avidity Partners Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$124K Hold
6,660
– – 0.02% 45
2026
Q1 		$79.5K Buy
+6,660
New +$74.6K 0.02% 45

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Avidity Partners Management's TRVI Position: Q2 2026 in Review

Avidity Partners Management held its Trevi Therapeutics (TRVI) position steady in Q2 2026 at 6,660 shares worth $124K. The position accounts for 0.02% of the portfolio, ranked #45.

Avidity Partners Management first reported a position in TRVI in Q1 2026 and has held it in 2 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Avidity Partners Management held 6,660 shares of Trevi Therapeutics worth $124K as of Q2 2026.
  • Avidity Partners Management left its Trevi Therapeutics share count unchanged in Q2 2026.
  • Trevi Therapeutics made up 0.02% of Avidity Partners Management's portfolio in Q2 2026, its #45 holding.
  • Avidity Partners Management first reported a position in Trevi Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Avidity Partners Management's 13F filing for Q2 2026, filed 14 Aug 2026.